Clinical Trial

A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This trial is a randomized, double-blind, three-period crossover Phase I Clinical Study conducted in Chinese adult overweight subjects to evaluate the safety, tolerability, PK and PD profiles of a single dose of GZR102 injection versus GZR4 injection and GZR18 injection given separately. Subjects undergo a screening phase of up to 3 weeks (D-21 to D-3). Eligible subjects are randomized in a 1:1:1:1:1:1 ratio into six dosing sequences, receiving single doses of GZR102 injection, GZR4 injection, and GZR18 injection across 3 cycles. A washout period of at least 1 week separates each cycle.
Trial Details
NCT Number NCT06974487
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Type 2 Diabetes
Enrollment 30 participants
Start Date 2025-05-08
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-16